Bisphosphonates are potent inhibitors of osteoclasts. They are used in cancer patients with skeletal metastasis, including breast, prostate, or lungcancer; and in patients with multiple myeloma. Bisphosphonates are also used to treat hypercalcemia of malignancy. (Refer to the PDQ summary on Hypercalcemia for more information.) Bisphosphonates reduce the risk of fracture and skeletal pain, improving the quality of life of patients with malignant bone disease. (Refer to the PDQ summary on Pain for more information.)
Children with cancer need information that is right for their age.
Studies show that children with cancer want to know about their illness and how it will be treated. The amount of information a child wants depends in part on his or her age. Most children worry about how their illness and treatment will affect their daily lives and the people around them. Studies also show that children have less doubt and fear when they are given information about their illness, even if it is bad news.
Bisphosphonate osteonecrosis (BON) is an oral complication of bisphosphonate therapy in cancer patients. First reported in 2003,[3,4] BON is defined as the unexpected appearance of exposed necrotic bone anywhere in the oral cavity of an individual who is receiving a bisphosphonate and who has not received radiation therapy to the head and neck. The exposed bone persists for 6 to 8 weeks despite the provision of standard dental care. It is also possible that symptoms of dental and/or periodontal disease may be present, without visible exposed bone. The occurrence of BON is based on cases reported in the literature, and occurrence ranges between 1% and 10% for patients receiving the intravenous formulation (pamidronate and zoledronic acid) and less than 1% for patients taking oral bisphosphonate.[6,7]
A study evaluating the literature until December 2008 found that the prevalence of BON can vary according to study design and the type of bisphosphonate used. For example, studies in which patient evaluation and follow-up are conducted by dental professionals seem to have an overall prevalence of 7.3%, whereas survey studies of large populations of patients have a prevalence of less than 1%. If the prevalence is calculated on the basis of type of bisphosphonate used, the prevalence of cases of BON when a combination of zoledronic acid and pamidronate is used over the course of therapy can be as high as 24.5%. The mandible is affected in approximately 68% of cases, the maxilla in about 28% of cases, and both jawbones in approximately 4% of cases. However, there have been reports of evidence of BON in other parts of the head and neck and skeleton.[10,11,12]